Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neoplasms 18Breast Neoplasms 16Lung Neoplasms 10Carcinoma, Non-Small-Cell Lung 6Prostatic Neoplasms 5Melanoma 5Colorectal Neoplasms 5Brain Neoplasms 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Skin Neoplasms 3Myeloproliferative Disorders 3Leukemia, Myeloid, Acute 3Kidney Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Hepatocellular 3Recurrence 2Neoplasm, Residual 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Lung Diseases 2Glioma 2Glioblastoma 2Genetic Predisposition to Disease 2Esophageal Neoplasms 2Endometrial Neoplasms 2

Interventions

cabozantinib 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
High Grade Neuroendocrine Neoplasms × Blood Specimen Collection × 90 days × Clear all
NCT04412629 2026-04-06

Cabozantinib in High Grade Neuroendocrine Neoplasms

Washington University School of Medicine

Phase 2 Active not recruiting
35 enrolled
Endocrine

High Grade Neuroendocrine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡